Comments
Zydus Cadila has received final approval from the US health regulator to market topiramate extended release capsules used for the treatment of seizures and migraine.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 25 mg, 50 mg and 100 mg, Zydus Cadila said in a BSE filing today.
The company said it will manufacture the drug at the group’s manufacturing facility at Moraiya, Ahmedabad.
Zydus Cadila has more than 170 approvals and has so far filed over 310 abbreviated new drug applications (ANDAs) since it had commenced filings in 2003-04.
Shares of the company’s listed entity Cadila Healthcare ended down by 0.47 per cent at Rs 444.15 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.